JY
SION

Jeff Yass’s Sionna Therapeutics SION Stock Holding History

Jeff Yass’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7,310
Closed -$292K – 14847
2026
Q1 		$293K Buy
+7,310
New +$279K ﹤0.01% 10908
2025
Q3 		– Sell
-14,834
Closed -$257K – 14281
2025
Q2 		$257K Buy
+14,834
New +$194K ﹤0.01% 10679

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Jeff Yass's SION Position: Q2 2026 in Review

Jeff Yass sold out of Sionna Therapeutics (SION) in Q2 2026, closing a stake of 7,310 shares — an estimated $292K sold.

Jeff Yass first reported a position in SION in Q2 2025 and held it in 2 quarters. The position peaked at $293K in Q1 2026. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Jeff Yass reported no remaining Sionna Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 7,310 Sionna Therapeutics shares in Q2 2026, an estimated $292K.
  • Jeff Yass first reported a position in Sionna Therapeutics in Q2 2025 and held it in 2 quarters.
  • Jeff Yass's Sionna Therapeutics position peaked at $293K in Q1 2026.
  • 146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.